Afinitor Disperz — CareFirst (Caremark)

Initial criteria

• Endometrial carcinoma: in combination with letrozole
• Uterine sarcoma: single agent for subsequent therapy

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months